Chemotherapy-related late adverse effects on ovarian function in female survivors of childhood and young adult cancer: A systematic review

Keyphrases

• Adult Life 33%
• Age at Diagnosis 33%
• Age at Menopause 33%
• Age at Treatment 33%
• Alkylating Agents 66%
• Amenorrhea 100%
• Anticancer Treatment 33%
• Breast Cancer Survivors 66%
• Busulfan 33%
• Cancer Survivors 66%
• Chemotherapy 100%
• Chemotherapy Effect 33%
• Chemotherapy-only 33%
• Comprehensive Search 33%
• Cyclophosphamide 33%
• High Age 33%
• High Risk 66%
• In Cancer 33%
• Late Effects 100%
• Methodological Limitations 33%
• Old Age 33%
• Ovarian Dysfunction 66%
• Ovarian Function 100%
• Premature Menopause 33%
• Procarbazine 66%
• Risk Factors 33%
• Treatment Duration 33%
• Women Survivors 100%
• Young Adult Cancer 100%

Medicine and Dentistry

• Adverse Event 100%
• Alkylating Antineoplastic Agent 66%
• Amenorrhea 100%
• Breast Cancer 66%
• Busulfan 33%
• Cancer in Young Adults 100%
• Cancer Therapy 33%
• Chemotherapy 100%
• Cyclophosphamide 33%
• Early Menopause 33%
• Lifespan 33%
• Malignant Neoplasm 66%
• Ovary Function 100%
• Ovary Insufficiency 66%
• Prevalence 66%
• Procarbazine 66%
• Systematic Review 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 100%
• Alkylating Agent 40%
• Amenorrhea 60%
• Breast Cancer 40%
• Busulfan 20%
• Chemotherapy Regimens 100%
• Cyclophosphamide 20%
• Early Menopause 20%
• Malignant Neoplasm 100%
• Ovary Insufficiency 40%
• Prevalence 40%
• Procarbazine 40%